Article
Pharmacology & Pharmacy
Jamie Garside, Qin Shen, Bernd Westermayer, Michiel van de Ven, Sonja Kroep, Viktor Chirikov, Ingolf Juhasz-Boess
Summary: This study found a strong correlation between progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) in the first-line treatment of advanced/recurrent endometrial cancer. Improvements in PFS/TTP are likely to translate into subsequent improvements in OS.
CLINICAL THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Chen Hu, Meihua Wang, Cai Wu, Heng Zhou, Cong Chen, Scott Diede
Summary: This study suggests that using restricted mean duration of response (DOR) in randomized phase 2 trials may be more sensitive and helpful than progression-free survival (PFS) and objective response rate (ORR) in estimating subsequent phase 3 conclusions, potentially complementing decision-making in future clinical development.
Article
Biochemistry & Molecular Biology
Gabriele Polonara, Denis Aiudi, Alessio Iacoangeli, Alessio Raggi, Matteo Maria Ottaviani, Ruggero Antonini, Maurizio Iacoangeli, Mauro Dobran
Summary: This study evaluates the prognostic significance of the extent of surgical resection in glioblastoma patients. The results show that maximal surgical resection involving areas of fluid-attenuated inversion recovery (FLAIR) abnormalities improves overall survival.
Article
Oncology
Rachel G. Woodford, Deborah D. X. Zhou, Peey-Sei Kok, Sally J. Lord, Michael Friedlander, Ian C. Marschner, R. John Simes, Chee Khoon Lee
Summary: Overall survival (OS) is the gold standard endpoint for oncology trials, but progression-free survival 2 (PFS-2) has been proposed as a surrogate endpoint due to delays in OS data maturation. A meta-analysis found that PFS-2 had a moderate correlation with OS across diverse tumors and therapies, performing consistently better than PFS-1 and objective response rate (ORR). PFS-2 should be included as a key endpoint in future randomized trials of solid tumors.
Article
Neurosciences
Banu Sacli-Bilmez, Ayca Ersen Danyeli, M. Cengiz Yakicier, Fuat Kaan Aras, M. Necmettin Pamir, Koray Ozduman, Alp Dincer, Esin Ozturk-Isik
Summary: This study analyzed the metabolic correlates of survival in Glioblastoma, IDH-wildtype, WHO grade-4 patients using H-1-MRS and found that Glx and GSH are important metabolic factors for patient survival.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Oncology
Fatima Tensaouti, Franck Desmoulin, Julia Gilhodes, Margaux Roques, Soleakhena Ken, Jean -Albert Lotterie, Georges Noel, Gilles Truc, Marie -Pierre Sunyach, Marie Charissoux, Nicolas Magne, Vincent Lubrano, Patrice Peran, Elizabeth Cohen-Jonathan Moyal, Anne Laprie
Summary: This study aimed to identify different components of glioblastoma subtypes using a large MRSI dataset and determine their association with progression-free survival. The results showed that pre-radiotherapy MRSI can reveal tumor heterogeneity and clusters with metabolic abnormalities and high lactate are predictive of PFS.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Ophthalmology
Felipe A. Medeiros, Alessandro A. Jammal
Summary: The purpose of this study was to investigate whether changes in standard automated perimetry (SAP) mean deviation (MD) over the initial 2-year follow-up period could predict events of visual field progression. The study followed 246 eyes of 168 glaucoma patients for up to 5 years and found that the rate of SAP MD change during the first 2 years was strongly predictive of subsequent visual field progression. These findings provide support for using the slope of MD change as a suitable endpoint for measuring progression in clinical trials.
Article
Oncology
Marco Rossi, Lorenzo Gay, Federico Ambrogi, Marco Conti Nibali, Tommaso Sciortino, Guglielmo Puglisi, Antonella Leonetti, Cristina Mocellini, Manuela Caroli, Susanna Cordera, Matteo Simonelli, Federico Pessina, Piera Navarria, Andrea Pace, Riccardo Soffietti, Roberta Ruda, Marco Riva, Lorenzo Bello
Summary: The study found that supratotal resection is strongly associated with good oncological outcomes in molecularly defined lower-grade gliomas, regardless of molecular subtypes and grading.
Article
Oncology
Anushka Walia, Jordan Tuia, Vinay Prasad
Summary: Composite outcome measures are commonly used in oncology research, but they have limitations such as vague definitions and complicated result comparisons. Knowing the breakdown of component events is essential for accurate interpretation of trial results and assessing the true benefit of interventions.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Boris Freidlin, Larissa A. Korde, Edward L. Korn
Summary: Recent therapeutic advances have improved patient survival in various cancer settings. To accelerate the development of new therapies, many cancer trials now designate OS as a secondary end point. This review assesses current practices and provides recommendations for designing and reporting trials with OS as a secondary end point to ensure data integrity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jiayi Li, Dongyan Cao
Summary: We developed two prognostic nomograms for predicting recurrence and long-term survival in patients with ovarian clear cell carcinoma (OCCC) after primary treatment, and validated them in patients from the same center. This tool, which uses variables specifically related to OCCC, was more accurate than the FIGO system, making it relatively easy to use in clinic for patient counseling, postoperative management, and follow-up for individual patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jordi Guzman-Casta, Sonia Carrasco-CaraChards, Jorge Guzman-Huesca, Carla Paola Sanchez-Rios, Rodrigo Riera-Sala, Jose Fabian Martinez-Herrera, Erika Sagrario Pena-Mirabal, Diana Bonilla-Molina, Jorge Arturo Alatorre-Alexander, Luis Manuel Martinez-Barrera, Jeronimo Rafael Rodriguez-Cid
Summary: Malignant pleural mesothelioma is a cancer with a poor prognosis that is typically diagnosed in advanced stages of the disease. Key prognostic factors for overall survival and progression-free survival include cell differentiation, treatment selection, and RECIST evaluation of patient response to treatment.
Article
Oncology
Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Anita Busacca, Domenica Matranga, Massimo Attanasio, Maria Reig, Antonio Craxi, Calogero Camma
Summary: The surrogate relationship between PFS and OS varies depending on treatment class and evaluation time-point in immunotherapy trials for HCC. In ICI trials, Q1-PFS and 12-month PFS-RMST are robust surrogate endpoints for OS.
Article
Oncology
Barbara Alves, Joana Peixoto, Sofia Macedo, Jorge Pinheiro, Bruno Carvalho, Paula Soares, Jorge Lima, Raquel T. Lima
Summary: This study evaluated the expression of MMP-2, MMP-9, YKL40, and VEGFA in a series of glioblastoma (GB) and their impact on patient outcome. High levels of VEGFA expression were significantly associated with improved progression-free survival after bevacizumab treatment, thus having potential as a tissue biomarker for predicting patients' response to bevacizumab. To a lesser extent, YKL40 also provided significant information regarding the extent of bevacizumab treatment. This study highlights the importance of studying secretome-associated proteins as GB biomarkers and identifies VEGFA as a promising marker for predicting response to bevacizumab.
Article
Oncology
Irene Tizianel, Mario Caccese, Francesca Torresan, Giuseppe Lombardi, Laura Evangelista, Filippo Crimi, Matteo Sepulcri, Maurizio Iacobone, Marta Padovan, Francesca Galuppini, Vittorina Zagonel, Carla Scaroni, Filippo Ceccato
Summary: The study found a significant improvement in survival rates for ACC patients after multidisciplinary team evaluation in 2013. Therefore, it is suggested that ACC patients should be referred to a tertiary center from the time of diagnosis in order to promptly apply all available treatments.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Mark P. van Opijnen, C. Mircea S. Tesileanu, Linda Dirven, Pim B. van der Meer, Maarten M. J. Wijnenga, Arnaud J. P. E. Vincent, Marike L. D. Broekman, Hendrikus J. Dubbink, Johan M. Kros, Sjoerd G. van Duinen, Marion Smits, Pim J. French, Martin J. van den Bent, Martin J. B. Taphoorn, Johan A. F. Koekkoek
Summary: IDHwt hLGG patients and IDHwt glioblastoma patients have similar incidence proportions of epilepsy during the entire disease course. However, the former has a significantly higher incidence of epilepsy before diagnosis and a significantly longer time between first seizure and diagnosis, indicating a distinct clinical course between the two subtypes.
Article
Rehabilitation
Ellen M. P. van Coevorden-van Loon, Herwin H. L. D. Horemans, Majanka H. Heijenbrok-Kal, Rita J. G. van den Berg-Emons, Robert Rozenberg, Arnaud J. P. E. Vincent, Gerard M. Ribbers, Martin J. van den Bent
Summary: This study aimed to evaluate physical fitness and its association with fatigue in patients with low grade glioma. The results showed that muscle strength and cardiorespiratory fitness were significantly decreased in these patients, and lower cardiorespiratory fitness was independently associated with higher levels of physical fatigue.
DISABILITY AND REHABILITATION
(2023)
Article
Oncology
Angelika Scherm, Franziska Maria Ippen, Peter Hau, Hansjoerg Baurecht, Wolfgang Wick, Jens Gempt, Helge Knuettel, Michael F. Leitzmann, Corinna Seliger
Summary: Glioblastoma is the most common malignant brain tumor in adults, and current standard treatment involves surgery followed by radiochemotherapy. This meta-analysis examined the efficacy of targeted therapies in newly diagnosed glioblastoma patients. The analysis showed that targeted agents did not significantly improve overall survival, but they did provide a benefit in progression-free survival, particularly in patients with an unmethylated MGMT promoter. Inhibition of VEGF with bevacizumab was the most effective in prolonging progression-free survival.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Matthias Preusser, Martin J. van den Bent
Review
Pharmacology & Pharmacy
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2023)
Review
Oncology
Maximilian J. Mair, Rupert Bartsch, Emilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortes, Hui K. Gan, Nancy U. Lin, Andrew B. Lassman, Patrick Y. Wen, Michael Weller, Martin van den Bent, Matthias Preusser
Summary: Antibody-drug conjugates (ADCs) have shown efficacy in various cancers, but their activity in the central nervous system (CNS) may be limited by the blood-brain barrier. This review summarizes the available clinical data on ADCs against primary and secondary brain tumors and ongoing trials. It also discusses the physical, biological, and molecular determinants of ADCs' CNS activity and potential strategies to improve drug delivery to brain tumors.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Andrew B. Lassman, Martin J. van den Bent
Article
Oncology
Fatemeh Arzanforoosh, Sebastian R. R. van der Voort, Fatih Incekara, Arnaud Vincent, Martin Van den Bent, Johan M. M. Kros, Marion Smits, Esther A. H. Warnert
Summary: Reliable insight into tumor microvasculature is crucial for disease monitoring and treatment response. Vessel size imaging (VSI), an emerging MRI technique, has demonstrated potential in accurately revealing microvasculature information in gliomas. However, its clinical application is limited, which was investigated in this study.
Article
Oncology
Sophie H. A. E. Derks, Joost L. M. Jongen, Edgar L. van der Meer, Li Shen Ho, Cleo Slagter, Arjen Joosse, Maja J. A. de Jonge, Joost W. Schouten, Esther Oomen-de Hoop, Martin J. van den Bent, Astrid A. M. van der Veldt
Summary: Cutaneous melanoma is highly prone to metastasize to the brain, with historically poor survival rates. However, the introduction of novel drugs such as targeted therapies and immune checkpoint inhibitors has significantly improved overall survival in patients with melanoma brain metastasis. This study demonstrates the benefits of stereotactic radiotherapy and immune checkpoint inhibitors, suggesting that ICIs should be the first choice of treatment after a diagnosis of MBM, if feasible.
Article
Oncology
Maarten M. J. Wijnenga, Sybren L. N. Maas, Vera van Dis, C. Mircea S. Tesileanu, Johan M. Kros, Linda Dirven, Hans M. Hazelbag, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Pim J. French, Martin J. van den Bent
NEURO-ONCOLOGY ADVANCES
(2023)
Article
Hematology
Daniel P. Noij, Martin van den Bent, Jeanette K. Doorduijn, Nick Wlazlo
Summary: We report a case of a 19-year-old patient who experienced two episodes of donor-derived PCNSL after undergoing allogeneic stem cell transplantation in childhood. Despite failed induction chemotherapy, successful consolidation therapy was achieved through a second allogeneic stem cell transplantation after conditioning with thiotepa, busulfan, and fludarabine.
ACTA HAEMATOLOGICA
(2023)
Review
Medicine, General & Internal
Martin J. van den Bent, Marjolein Geurts, Pim J. French, Marion Smits, David Capper, Jacoline E. C. Bromberg, Susan M. Chang
Summary: The most common adult-type primary CNS tumors are diffuse gliomas, but there are also various rare CNS tumor types. The classification of these tumors is increasingly based on molecular diagnostics. Surgery is the mainstay of treatment for gliomas, and early surgery is recommended for patients with histologically low-grade tumors. Standard treatment for adult-type diffuse glioma consists of radiotherapy and chemotherapy. Targeted treatments and immunotherapy are still in the early stages of development for the treatment of adult-type gliomas.
Article
Biochemistry & Molecular Biology
Niklas Grassl, Isabel Poschke, Katharina Lindner, Lukas Bunse, Iris Mildenberger, Tamara Boschert, Kristine Jahne, Edward W. Green, Ingrid Hulsmeyer, Simone Juenger, Tobias Kessler, Abigail K. Suwala, Philipp Eisele, Michael O. Breckwoldt, Peter Vajkoczy, Oliver M. Grauer, Ulrich Herrlinger, Joerg-Christian Tonn, Monika Denk, Felix Sahm, Martin Bendszus, Andreas von Deimling, Frank Winkler, Wolfgang Wick, Michael Platten, Katharina Sahm
Summary: The treatment of H3K27M-vac in patients with progressive H3K27M(+) diffuse midline glioma demonstrates its safety and immunogenicity, and may improve patients' survival.
Article
Oncology
Christoper Kraemer, Michael Kilian, Yu-Chan Chih, Alexandros Kourtesakis, Dirk C. Hoffmann, Tamara Boschert, Philipp Koopmann, Khwab Sanghvi, Alice De Roia, Stefanie Jung, Kristine Jaehne, Bryan Day, Lenny D. Shultz, Miriam Ratliff, Richard Harbottle, Edward W. Green, Rainer Will, Wolfgang Wick, Michael Platten, Lukas Bunse
Summary: This study identified an antigen that is overexpressed in human gliomas and can induce specific cytotoxic T cell responses through vaccination, indicating its potential therapeutic efficacy in treating glioblastoma.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
